ZNF484 Inhibitors

Inhibitors of the PI3K/AKT pathway, such as Wortmannin and LY294002, can alter downstream signaling processes that may affect the functional role of ZNF484 in cell survival and proliferation. The mTOR pathway, targeted by Sirolimus, is central to cellular growth and protein synthesis, and its inhibition can have a downstream effect on the synthesis and activity of ZNF484. Similarly, inhibitors of the MAPK/ERK pathway, like PD98059 and U0126, can change the phosphorylation state of various proteins, potentially including those that interact with or regulate ZNF484.

Inhibition of the JNK and p38 MAPK pathways by compounds such as SP600125 and SB203580 respectively, can modulate cellular responses to stress and inflammation, which might alter the activity or expression of ZNF484. NF-kB signaling, which can be affected by compounds like Curcumin and Triptolide, plays a crucial role in the regulation of gene expression in response to stimuli, and its inhibition can change the expression levels of a range of genes, potentially including those associated with ZNF484. Lastly, proteasome inhibitors like Bortezomib prevent the degradation of many proteins, which can result in increased levels of ZNF484 if it is normally subject to proteasomal degradation.